European Companies Search Engine
EU funding (€3,825,128): Chromatin and Metabolism Chromatin-metabolism interactions as targets for healthy living Hor 1 Mar 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Chromatin and Metabolism Chromatin-metabolism interactions as targets for healthy living
Metabolic disorders are at pandemic levels. Based on recent estimates, ~50% of Europeans are overweight, 20% are obese and 10% have type II diabetes. Obesity and insulin resistance impact European health to the tune of €110 billion per year. These disorders have genetic, nutritional and lifestyle causes. However, the molecular mechanisms that link nutrients and lifestyle to gene activity and chromatin are poorly understood, and drug targets are only starting to be identified. Pioneering experiments by ChroMe labs now reveal how sugars, exercise, the gut microbiome and novel drugs regulate chromatin. These novel links promise to substantially improve our understanding and treatment of metabolic disorders. National governments and the EU invest major resources to address the burden of the “metabolic syndrome”. However, there is an urgent need for expert human capital able to dissect metabolic diseases, exploit new targets and establish innovative therapies. No local nor international program currently provides adequate training at this emerging interface of chromatin and metabolism. ChroMe establishes a timely and intersectorial ETN that exploits Europe’s strengths in epigenetics, physiology and medicine to translate our molecular knowledge of chromatin–metabolism interactions into therapies. Our ESRs receive advanced training in emerging technologies, bioinformatic and translational approaches, and all engage in collaborative PhD projects co-supervised by academia and industry. ChroMe’s extensive transferable skills, dissemination and public engagement program equips our ESRs with the experience and personal network needed for a career in metabolic health. By systematically involving the non-academic sector at every level in our research, training and management, ChroMe will craft future European leaders with the necessary knowledge and skills to fight the metabolic syndrome pandemic.
Funded Companies:
| Company name | Funding amount |
| 4 SC AG | €249,216 |
| Biobam Bioinformatics SL | €247,873 |
| Chronos Therapeutics Ltd. | €273,288 |
| Fundacio Institut de Recerca Contra La Leucemia Josep Carreras | €495,746 |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit UND Umwelt GmbH | €249,216 |
| Imperial College of Science Technology and Medicine | €273,288 |
| Institut National de la Sante et de la Recherche Medicale | €262,876 |
| Karolinska Institutet | €263,659 |
| Ludwig-Maximilians-Universitaet Muenchen | €747,649 |
| MAX-Planck-Gesellschaft ZUR Forderung DER Wissenschaften e. V. | €249,216 |
| Societe DES Produits Nestle SA | €265,227 |
| Universitat Rovira i Virgili | €247,873 |
Source: https://cordis.europa.eu/project/id/675610
The filing refers to a past date, and does not necessarily reflect the current state.